safety and efficacay of unani formulation Majoon Mussaffi-Azam in Busoor(skin eruptions).

Clinical validation of Unani pharmacopoeial formulation Majoon Mussaffi Azam in Busoor(Skin eruptions) - nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/09/074512

Enrollment

Registered

2024-09-27

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L709- Acne, unspecified

Interventions

Intervention1: Majoon-musaffi-e-Azam: It is a semisolid preparation and is to be given orally 7gms twice daily for 6 weeks

Eligibility

Inclusion criteria

Inclusion criteria: Frequently occurrence of Busoor, with or without association of following features. 1.Humra (Erythema) 2 .Waja (Pain) 3. Hikka (Itching

Exclusion criteria

Exclusion criteria: 1 .Patients of Busoor associated with fever. 2. Patients with other inflammatory and suppurated conditions of skin e.g. Abscess, Carbuncle, and Cellulitis. 3.Patients with features of Cellulitis 4.Patients with diabetes mellitus 5.Patients with disease required long term treatment e.g. Metabolic Disorders, specific infectious disease and cancer etc. 6.Pregnancy and lactation

Design outcomes

Primary

Measure	Time frame
The lesion will be evaluated according to its number, size, and associated symptoms. Grading on the basis of the number of lesions will be recordedTimepoint: Baseline,Day 7,Day 14,Day 28	—

Secondary

Measure	Time frame
NILTimepoint: nil	—

Countries

India

Contacts

Public ContactDr Huma

Regional research institute of unani medicine

humaccrum@gmail.com9796550059

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026